Why the study?
Does 3 weeks' anticoagulation therapy compared to 6 weeks' anticoagulation prevent recurrence in hospital in-patients treated for pulmonary embolism and/or deep vein thrombosis?
Does 3 weeks' anticoagulation therapy compared to 6 weeks' anticoagulation prevent recurrence in hospital in-patients treated for pulmonary embolism and/or deep vein thrombosis?
Three weeks of anticoagulation with heparin and warfarin appears adequate and comparable to six weeks for preventing recurrence in patients with venous thromboembolism without persisting risk factors.
Answers are grounded in this paper and cite their sources.
Supports 3-week anticoagulation for VTE without persisting risk factors; confirms adequacy of abbreviated therapy in this RCT population.
One hundred hospital in-patients treated for pulmonary embolism (PE) and/or deep vein thrombosis (DVT) were randomly allocated to receive 3 or 6 weeks' anticoagulation with heparin and warfarin. At one year recurrence rates were 12% in the 6 week group and 10% in those treated for 3 weeks. No patient died as a result of recurrence. Our study suggests that 3 weeks' anticoagulation therapy, using intravenous heparin for the first 5 days and warfarin from the third day, is adequate for patients without persisting risk factors.
No takes yet. Share an insight, caveat, or question.
Fennerty et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: